Eli Lilly’s Imlygic FDA Delay: What This Might Mean for the Bladder Cancer Market
Eli Lilly and Company’s Imlygic (talimogene laherparepvec; T-VEC), an oncolytic virus therapy for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle-invasive bladder cancer (NMIBC), has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA). The CRL…